MTOR and neoplasm: Indeed, popular targeted therapies for RMS include mTOR and Hedgehog inhibitors and RTK-specific monoclonal antibodies or small-molecule inhibitors but, while an initial response is observed with these treatments, the disease often continues to progress and/or tumour drug-resistance develops.